{"success":true,"data":{"pressRelease":{"id":"157361","rtpr_id":"nGNX1jk3Rn-20260930","ticker":"IMMX","exchange":"NASDAQ","all_tickers":["IMMX"],"title":"Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock","author":"Globe Newswire","published_at":"2026-09-30T21:15:00.091Z","article_body":"LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc.\n(“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global\nleader in relapsed/refractory AL Amyloidosis, today announced the closing of\nits previously announced underwritten registered offering of 11,363,637 shares\nof its common stock at a public offering price of $11.00 per share. The net\nproceeds to Immix from the offering, after deducting the underwriting\ndiscounts, commissions and other offering expenses, were approximately $117.1\nmillion.\n\nImmix intends to use the net proceeds from this offering to fund NXC-201\ndevelopment, working capital and general corporate purposes.\n\nJ.P. Morgan acted as the sole book-running manager for the offering. The\noffering included participation from leading U.S. biotechnology institutional\ninvestors and mutual funds.\n\nThe shares of common stock described above were offered and sold by the\nCompany pursuant to a shelf registration statement on Form S-3 (File No.\n333-292665), including a base prospectus, filed with the U.S. Securities and\nExchange Commission (the “SEC”) on January 9, 2026, and declared effective\non January 22, 2026. A prospectus supplement and accompanying prospectus\ndescribing the terms of the offering was filed with the SEC and is available\non the SEC’s website located at www.sec.gov. Copies of the prospectus\nsupplement and the accompanying prospectus related to this offering may be\nobtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,\n1155 Long Island Avenue, Edgewood, New York 11717, or by email\nat prospectus-eq_fi@jpmchase.com and\npostsalemanualrequests@broadridge.com. \n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy any of the securities described herein, nor shall there be\nany sale of these securities in any state or other jurisdiction in which such\noffer, solicitation or sale would be unlawful prior to the registration or\nqualification under the securities laws of any such state or other\njurisdiction.\n\nAbout Immix Biopharma, Inc.\n\nImmix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL\nAmyloidosis. AL Amyloidosis is a devastating disease where the immune system,\nthat’s supposed to protect, instead produces toxic light chains, clogging up\nthe heart, kidney and liver, causing organ failure and death. Our lead\ncandidate is sterically-optimized BCMA-targeted chimeric antigen receptor T\n(CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder\n“digital filter” designed to filter out non-specific activation. NXC-201\nteaches the immune system to recognize and eliminate the source of the toxic\nlight chains. NXC-201 is being evaluated in the U.S. multi-center study for\nrelapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a\npotentially registrational design. NXC-201 has been awarded Breakthrough\nTherapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by\nthe US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.\n\nContacts\n\nMike Moyer\nLifeSci Advisors\nmmoyer@lifesciadvisors.com \n\nCompany Contact\n\nGabriel Morris, CFO\nirteam@immixbio.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b46d5687-65de-44df-81d5-e36f2665d8e7)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1jk3Rn-20260930","title":"Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock","author":"Globe Newswire","ticker":"IMMX","created":"2026-09-30T21:15:00.091Z","tickers":["IMMX"],"exchange":"NASDAQ","article_body":"LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc.\n(“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global\nleader in relapsed/refractory AL Amyloidosis, today announced the closing of\nits previously announced underwritten registered offering of 11,363,637 shares\nof its common stock at a public offering price of $11.00 per share. The net\nproceeds to Immix from the offering, after deducting the underwriting\ndiscounts, commissions and other offering expenses, were approximately $117.1\nmillion.\n\nImmix intends to use the net proceeds from this offering to fund NXC-201\ndevelopment, working capital and general corporate purposes.\n\nJ.P. Morgan acted as the sole book-running manager for the offering. The\noffering included participation from leading U.S. biotechnology institutional\ninvestors and mutual funds.\n\nThe shares of common stock described above were offered and sold by the\nCompany pursuant to a shelf registration statement on Form S-3 (File No.\n333-292665), including a base prospectus, filed with the U.S. Securities and\nExchange Commission (the “SEC”) on January 9, 2026, and declared effective\non January 22, 2026. A prospectus supplement and accompanying prospectus\ndescribing the terms of the offering was filed with the SEC and is available\non the SEC’s website located at www.sec.gov. Copies of the prospectus\nsupplement and the accompanying prospectus related to this offering may be\nobtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,\n1155 Long Island Avenue, Edgewood, New York 11717, or by email\nat prospectus-eq_fi@jpmchase.com and\npostsalemanualrequests@broadridge.com. \n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy any of the securities described herein, nor shall there be\nany sale of these securities in any state or other jurisdiction in which such\noffer, solicitation or sale would be unlawful prior to the registration or\nqualification under the securities laws of any such state or other\njurisdiction.\n\nAbout Immix Biopharma, Inc.\n\nImmix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL\nAmyloidosis. AL Amyloidosis is a devastating disease where the immune system,\nthat’s supposed to protect, instead produces toxic light chains, clogging up\nthe heart, kidney and liver, causing organ failure and death. Our lead\ncandidate is sterically-optimized BCMA-targeted chimeric antigen receptor T\n(CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder\n“digital filter” designed to filter out non-specific activation. NXC-201\nteaches the immune system to recognize and eliminate the source of the toxic\nlight chains. NXC-201 is being evaluated in the U.S. multi-center study for\nrelapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a\npotentially registrational design. NXC-201 has been awarded Breakthrough\nTherapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by\nthe US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.\n\nContacts\n\nMike Moyer\nLifeSci Advisors\nmmoyer@lifesciadvisors.com \n\nCompany Contact\n\nGabriel Morris, CFO\nirteam@immixbio.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b46d5687-65de-44df-81d5-e36f2665d8e7)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-30T21:15:00.125063359Z","server_sent_at_ms":1790802900125},"received_at":"2026-09-30T21:15:00.178Z","source_url":null},"analysis":{"id":"146030","press_release_id":"157361","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["equity dilution of ~11.4M shares at a clinical-stage biotech","portion of proceeds allocated to general corporate purposes"],"eventType":"offering","narrative":"Immix Biopharma closed its previously announced underwritten offering of 11,363,637 shares at $11.00 per share, raising $125 million gross and approximately $117.1 million in net proceeds.\n\nJ.P. Morgan was sole book-running manager, with participation from U.S. biotech institutional investors and mutual funds.\n\nProceeds will fund NXC-201 development, working capital and general corporate purposes, extending runway for the potentially registrational NEXICART-2 study in relapsed/refractory AL Amyloidosis.","sentiment":"neutral","agentHooks":{"shouldPost":true,"suggestedAngle":"$117M net raise funds NXC-201 registrational-path development but adds meaningful share count for IMMX."},"keyFigures":{"offeringPrice":11,"sharesOffered":11363637,"customDimensions":{"net_proceeds":"$117.1 million"}},"namedEntities":{"people":[{"name":"Gabriel Morris","role":"CFO"},{"name":"Mike Moyer","role":"LifeSci Advisors (media contact)"}],"products":["NXC-201","NEXICART-2 (NCT06097832)"],"companies":[{"name":"Immix Biopharma, Inc.","ticker":"IMMX","relationship":"filer/issuer"},{"name":"J.P. Morgan","relationship":"sole book-running manager/underwriter"},{"name":"LifeSci Advisors","relationship":"investor relations"}],"dollarAmounts":[{"amount":"$125 million","context":"gross proceeds of underwritten offering (title)"},{"amount":"$11.00","context":"public offering price per share"},{"amount":"$117.1 million","context":"net proceeds after underwriting discounts and expenses"}]},"materialImpact":{"score":3,"reasoning":"Closing of a $125M underwritten equity offering causing ~11.4M shares of dilution, but it was previously announced and pricing is disclosed; proceeds fund the lead NXC-201 program. Not a surprise event, but materially dilutive for a clinical-stage biotech."},"tickerRelevance":{"others":[],"primary":"IMMX"},"globalImportance":30,"audienceRelevance":20,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"offering-closing-dilution","issuerAuthored":true}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"neutral","material_impact_score":3,"narrative":"Immix Biopharma closed its previously announced underwritten offering of 11,363,637 shares at $11.00 per share, raising $125 million gross and approximately $117.1 million in net proceeds.\n\nJ.P. Morgan was sole book-running manager, with participation from U.S. biotech institutional investors and mutual funds.\n\nProceeds will fund NXC-201 development, working capital and general corporate purposes, extending runway for the potentially registrational NEXICART-2 study in relapsed/refractory AL Amyloidosis.","key_figures":{"offeringPrice":11,"sharesOffered":11363637,"customDimensions":{"net_proceeds":"$117.1 million"}},"named_entities":{"people":[{"name":"Gabriel Morris","role":"CFO"},{"name":"Mike Moyer","role":"LifeSci Advisors (media contact)"}],"products":["NXC-201","NEXICART-2 (NCT06097832)"],"companies":[{"name":"Immix Biopharma, Inc.","ticker":"IMMX","relationship":"filer/issuer"},{"name":"J.P. Morgan","relationship":"sole book-running manager/underwriter"},{"name":"LifeSci Advisors","relationship":"investor relations"}],"dollarAmounts":[{"amount":"$125 million","context":"gross proceeds of underwritten offering (title)"},{"amount":"$11.00","context":"public offering price per share"},{"amount":"$117.1 million","context":"net proceeds after underwriting discounts and expenses"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-30T21:15:05.073Z","global_importance":30,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"offering-closing-dilution","issuerAuthored":true}},"durationMs":4880,"modelName":"glm-5.3-flashx"}}